Pharma Mar SA - Company Profile
Powered by 
All the sales intelligence you need on Pharma Mar SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pharma Mar SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pharma Mar SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company. The company's main activities include discovering new anti-tumour molecules of marine origin and advancing them through various clinical phases. The company’s marketed products include Yondelis (trabectedin), an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. The company targets the global oncology market, with a focus on the world's main oncology markets. It also develops RNAi candidates for the treatment of retinal diseases. The company operates through its subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the US. Pharma Mar is headquartered in Colmenar Viejo, Madrid, Spain.
Headquarters
Spain
Address
Colmenar Viejo, Madrid, 28770
Website
www.pharmamar.com/es
Telephone
34 918 466000
No of Employees
505
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHM (MCE)
Revenue (2025)
$249.8M
26.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
187%
(2025 vs 2024)
Market Cap*
$2.1B
Net Profit Margin (2025)
XYZ
126.7%
(2025 vs 2024)
* As of and is in US$
Pharma Mar SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Yondelis (Trabectedin): Soft Tissue Sarcoma and Ovarian Cancer | Yondelis |
| Zepzelca (Lurbinectedin): Small Cell Lung Cancer and Solid Tumors | Aplidin |
| Aplidin: Multiple Myeloma | Zepzelca |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In April, the company signed an agreement with Merck for the development and commercialisation of Zepzelca a novel transcription inhibitor for the treatment of small cell lung cancer, in Japan. |
| 2025 | Regulatory Approval | In May, the company received approval from Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT) for the metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. |
| 2025 | Regulatory Approval | In October, the company received approval from U.S Food and Drug Administration (FDA) for for Zepzelca and atezolizumab. |
Competitor Comparison
| Key Parameters | Pharma Mar SA | Pfizer Inc | Bristol-Myers Squibb Co | Ability Pharmaceuticals SL | GP Pharm SA |
|---|---|---|---|---|---|
| Headquarters | Spain | United States of America | United States of America | Spain | Spain |
| City | Madrid | New York City | Princeton | Cerdanyola | Barcelona |
| State/Province | Madrid | New York | New Jersey | Barcelona | Barcelona |
| No. of Employees | 505 | 75,000 | 32,500 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jose Maria Fernandez Sousa-Faro, Ph.D. | Chairman; Chief Executive Officer | Executive Board | - | - |
| Maria Luisa de Francia Caballero | Chief Financial Officer | Senior Management | - | - |
| Pedro Fernandez Puentes | Vice Chairman | Executive Board | - | - |
| Luis Mora Capitan | General Manager - Oncology and Virology Business Units | Senior Management | - | - |
| Juan Gomez Pulido | Secretary | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer